BIOCRYST PHARMACEUTICALS, INC. (BCRX)

Every figure this model derived for BCRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,758,000 PaymentsToAcquireProductiveAssets 2026-06-30
cash 352,573,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 484,683,000 AssetsCurrent 2026-06-30
current liabilities 208,846,000 LiabilitiesCurrent 2026-06-30
equity -454,289,000 StockholdersEquity 2026-06-30
interest expense 75,287,000 InterestExpenseNonoperating 2026-06-30
ocf 376,135,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 940,613,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 73,113,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BCRX on one particular measure came for.

RatioValue
cash operating margin-25.42
current ratio2.47
current ratio reported2.32
deferred revenue growth-100.0
dilution pct5.75
fcf margin39.7
growth cv1.45
interest cover-4.16
operating margin-33.29
owner earnings margin31.92
revenue growth68.72
revenue growth per share59.54
rule of 4035.43
sbc pct revenue7.77

What to be careful about

What this model itself distrusts about BCRX's figures. Written by the derivation as it ran, not added afterwards.